AZ ORIN1001-002 D4325C00001: Phase 1b Double-Blind, Placebo-Controlled, Ascending Dose Trial: ORIN1001 in Subjects with Idiopathic Pulmonary Fibrosis
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
ORINOVE, Inc
Start Date
April 8, 2022
End Date
December 3, 2024
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
ORINOVE, Inc
Start Date
April 8, 2022
End Date
December 3, 2024